Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relationship of Clinical Course with Prior Therapy in anti-GD2 Immunotherapy (JN-GD2-23)
jRCT1050230140Completed
- Start
- Feb 2024
- Countries
- 1
01
Overview
Trial in neuroblastoma (2 arms), sponsored by none. Primary endpoint: GD2 Immunotherapy Completion by Allogeneic Transplant History. Started Feb 2024; status: completed.
02
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT1050230140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050230140.